BR112014018712A8 - Derivados de morfolinila úteis como inibidores de mogat-2 - Google Patents
Derivados de morfolinila úteis como inibidores de mogat-2Info
- Publication number
- BR112014018712A8 BR112014018712A8 BR112014018712A BR112014018712A BR112014018712A8 BR 112014018712 A8 BR112014018712 A8 BR 112014018712A8 BR 112014018712 A BR112014018712 A BR 112014018712A BR 112014018712 A BR112014018712 A BR 112014018712A BR 112014018712 A8 BR112014018712 A8 BR 112014018712A8
- Authority
- BR
- Brazil
- Prior art keywords
- morpholinil
- mogat
- inhibitors
- derivatives useful
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
DERIVADOS DE MORFOLINILA ÚTEIS COMO INIBIDORES DE MOGAT-2. A presente invenção fornece compostos da Fórmula I ou um sal farmacêutico dos mesmos, métodos de tratamento de hipertrigliceridemia usando os compostos; e um processo para a preparação dos compostos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12382037 | 2012-01-31 | ||
US201261617093P | 2012-03-29 | 2012-03-29 | |
EP12382433 | 2012-11-06 | ||
PCT/US2013/022828 WO2013116065A1 (en) | 2012-01-31 | 2013-01-24 | Novel morpholinyl derivatives useful as mogat-2 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014018712A2 BR112014018712A2 (pt) | 2017-06-20 |
BR112014018712A8 true BR112014018712A8 (pt) | 2017-07-11 |
Family
ID=48905712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014018712A BR112014018712A8 (pt) | 2012-01-31 | 2013-01-24 | Derivados de morfolinila úteis como inibidores de mogat-2 |
Country Status (24)
Country | Link |
---|---|
US (1) | US8993568B2 (pt) |
EP (1) | EP2809661B1 (pt) |
JP (1) | JP5852269B2 (pt) |
KR (1) | KR20140107641A (pt) |
CN (1) | CN104080777B (pt) |
AP (1) | AP2014007793A0 (pt) |
AU (1) | AU2013215549B2 (pt) |
BR (1) | BR112014018712A8 (pt) |
CA (1) | CA2859992A1 (pt) |
CL (1) | CL2014001862A1 (pt) |
CO (1) | CO7020914A2 (pt) |
CR (1) | CR20140325A (pt) |
DO (1) | DOP2014000177A (pt) |
EA (1) | EA024182B1 (pt) |
ES (1) | ES2571577T3 (pt) |
GT (1) | GT201400169A (pt) |
HK (1) | HK1199024A1 (pt) |
IL (1) | IL233542A0 (pt) |
MX (1) | MX2014008604A (pt) |
PE (1) | PE20141789A1 (pt) |
PH (1) | PH12014501712B1 (pt) |
SG (1) | SG11201404508XA (pt) |
WO (1) | WO2013116065A1 (pt) |
ZA (1) | ZA201405227B (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2807147A1 (en) | 2012-01-23 | 2014-12-03 | Eli Lilly and Company | Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors |
CA2859992A1 (en) | 2012-01-31 | 2013-08-08 | Eli Lilly And Company | Novel morpholinyl derivatives useful as mogat-2 inhibitors |
TW201343629A (zh) | 2012-01-31 | 2013-11-01 | Lilly Co Eli | 可作為mogat-2抑制劑之新穎芐磺醯胺衍生物 |
CA2886831A1 (en) | 2012-11-06 | 2014-05-15 | Eli Lilly And Company | Novel benzyl sulfonamide compounds useful as mogat-2 inhibitors |
WO2017110841A1 (ja) | 2015-12-21 | 2017-06-29 | 塩野義製薬株式会社 | Mgat2阻害活性を有する非芳香族複素環誘導体 |
TWI782056B (zh) | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | 具有mgat2抑制活性的縮合環衍生物 |
TWI840489B (zh) | 2019-01-11 | 2024-05-01 | 日商鹽野義製藥股份有限公司 | 酮衍生物 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5889006A (en) | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
GB9702194D0 (en) | 1997-02-04 | 1997-03-26 | Lilly Co Eli | Sulphonide derivatives |
CA2338994A1 (en) | 1998-07-31 | 2000-02-10 | Paul Leslie Ornstein | Sulfonamide derivatives |
AU5233999A (en) | 1998-07-31 | 2000-02-21 | Eli Lilly And Company | Alkenyl sulphonamide derivatives |
GB0408777D0 (en) | 2004-04-20 | 2004-05-26 | Glaxo Group Ltd | Compounds |
EP1659113A1 (en) | 2004-11-08 | 2006-05-24 | Evotec AG | Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) |
EP1655283A1 (en) | 2004-11-08 | 2006-05-10 | Evotec OAI AG | 11beta-HSD1 Inhibitors |
WO2008038768A1 (fr) * | 2006-09-28 | 2008-04-03 | Dainippon Sumitomo Pharma Co., Ltd. | Composé ayant une structure de pyrimidine bicyclique et composition pharmaceutique comprenant le composé |
TW200831092A (en) * | 2006-12-21 | 2008-08-01 | Astrazeneca Ab | Therapeutic agents |
RU2010126828A (ru) * | 2007-12-05 | 2012-01-10 | Астразенека Аб (Se) | Производные морфолина в качестве средств против ожирения |
US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
JPWO2009119726A1 (ja) | 2008-03-28 | 2011-07-28 | Msd株式会社 | メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体 |
CA2725949A1 (en) | 2008-06-04 | 2009-12-10 | Astrazeneca Ab | New pyridine derivatives as leptin receptor modulator mimetics |
WO2010095767A1 (en) | 2009-02-23 | 2010-08-26 | Banyu Pharmaceutical Co.,Ltd. | Pyrimidin-4(3h)-one derivatives |
JP2014051434A (ja) | 2010-12-28 | 2014-03-20 | Dainippon Sumitomo Pharma Co Ltd | 二環性ピリミジン誘導体 |
EP2807147A1 (en) | 2012-01-23 | 2014-12-03 | Eli Lilly and Company | Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors |
CA2859992A1 (en) | 2012-01-31 | 2013-08-08 | Eli Lilly And Company | Novel morpholinyl derivatives useful as mogat-2 inhibitors |
TW201343629A (zh) | 2012-01-31 | 2013-11-01 | Lilly Co Eli | 可作為mogat-2抑制劑之新穎芐磺醯胺衍生物 |
CA2886831A1 (en) | 2012-11-06 | 2014-05-15 | Eli Lilly And Company | Novel benzyl sulfonamide compounds useful as mogat-2 inhibitors |
-
2013
- 2013-01-24 CA CA2859992A patent/CA2859992A1/en not_active Abandoned
- 2013-01-24 BR BR112014018712A patent/BR112014018712A8/pt not_active IP Right Cessation
- 2013-01-24 CN CN201380007113.8A patent/CN104080777B/zh not_active Expired - Fee Related
- 2013-01-24 WO PCT/US2013/022828 patent/WO2013116065A1/en active Application Filing
- 2013-01-24 JP JP2014554806A patent/JP5852269B2/ja not_active Expired - Fee Related
- 2013-01-24 EA EA201491227A patent/EA024182B1/ru not_active IP Right Cessation
- 2013-01-24 PE PE2014001194A patent/PE20141789A1/es not_active Application Discontinuation
- 2013-01-24 US US14/372,833 patent/US8993568B2/en not_active Expired - Fee Related
- 2013-01-24 ES ES13702564T patent/ES2571577T3/es active Active
- 2013-01-24 SG SG11201404508XA patent/SG11201404508XA/en unknown
- 2013-01-24 KR KR1020147021129A patent/KR20140107641A/ko active IP Right Grant
- 2013-01-24 EP EP13702564.9A patent/EP2809661B1/en active Active
- 2013-01-24 MX MX2014008604A patent/MX2014008604A/es unknown
- 2013-01-24 AP AP2014007793A patent/AP2014007793A0/xx unknown
- 2013-01-24 AU AU2013215549A patent/AU2013215549B2/en not_active Ceased
-
2014
- 2014-07-07 IL IL233542A patent/IL233542A0/en unknown
- 2014-07-08 CR CR20140325A patent/CR20140325A/es unknown
- 2014-07-15 CL CL2014001862A patent/CL2014001862A1/es unknown
- 2014-07-16 ZA ZA2014/05227A patent/ZA201405227B/en unknown
- 2014-07-24 CO CO14161421A patent/CO7020914A2/es unknown
- 2014-07-29 GT GT201400169A patent/GT201400169A/es unknown
- 2014-07-30 DO DO2014000177A patent/DOP2014000177A/es unknown
- 2014-07-30 PH PH12014501712A patent/PH12014501712B1/en unknown
- 2014-12-11 HK HK14112464.6A patent/HK1199024A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL233542A0 (en) | 2014-08-31 |
PH12014501712A1 (en) | 2014-10-13 |
SG11201404508XA (en) | 2014-10-30 |
AU2013215549B2 (en) | 2015-09-03 |
US20150005305A1 (en) | 2015-01-01 |
MX2014008604A (es) | 2014-08-22 |
JP2015504917A (ja) | 2015-02-16 |
BR112014018712A2 (pt) | 2017-06-20 |
PH12014501712B1 (en) | 2014-10-13 |
WO2013116065A1 (en) | 2013-08-08 |
ES2571577T3 (es) | 2016-05-26 |
CO7020914A2 (es) | 2014-08-11 |
GT201400169A (es) | 2015-08-27 |
CN104080777B (zh) | 2015-12-09 |
HK1199024A1 (zh) | 2015-06-19 |
EA201491227A1 (ru) | 2015-01-30 |
CR20140325A (es) | 2014-08-25 |
EP2809661A1 (en) | 2014-12-10 |
AP2014007793A0 (en) | 2014-07-31 |
CA2859992A1 (en) | 2013-08-08 |
AU2013215549A1 (en) | 2014-07-17 |
PE20141789A1 (es) | 2014-11-19 |
EP2809661B1 (en) | 2016-04-06 |
KR20140107641A (ko) | 2014-09-04 |
CL2014001862A1 (es) | 2014-11-14 |
US8993568B2 (en) | 2015-03-31 |
DOP2014000177A (es) | 2014-08-31 |
CN104080777A (zh) | 2014-10-01 |
EA024182B1 (ru) | 2016-08-31 |
ZA201405227B (en) | 2016-05-25 |
JP5852269B2 (ja) | 2016-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122707T1 (el) | Ετεροκυκλικοι αναστολεις γλουταμινασης | |
BR112016014020A8 (pt) | moduladores de tetra-hidropiridopirazinas de gpr6. | |
BR112017011972A2 (pt) | derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais | |
EA201500207A1 (ru) | Гетероароматические соединения в качестве ингибиторов втк | |
BR112014018712A8 (pt) | Derivados de morfolinila úteis como inibidores de mogat-2 | |
EA201400412A1 (ru) | ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
BR112014027236A2 (pt) | pirrolidinas substituídas como um fator inibidor de xia para o tratamento de doenças tromboembolíticas | |
BR112014003681A8 (pt) | composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições | |
BR112017007123A2 (pt) | derivados de tetrahidroisoquinolina | |
ECSP14013211A (es) | Nuevo derivado de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes | |
BR112015004547A2 (pt) | compostos, composição farmacêutica, uso de um composto e método para o tratamento ou melhoria do cãncer | |
BR112014018636A8 (pt) | Derivados de benzil sulfonamida úteis como inibidores de mogat-2 | |
BR112016007396A2 (pt) | derivados de cetona pirídicos, método de preparação dos mesmos e aplicação farmacêutica dos mesmos | |
BR112014032053A2 (pt) | composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção | |
BR112015004029A8 (pt) | processo para preparação de teneligliptina, de um composto ou de sal ou hidrato do mesmo, e, composto | |
CL2014002661A1 (es) | Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer. | |
BR112017009471A2 (pt) | síntese de copanlisib e seu sal de di-hidrocloreto. | |
BR112015002493A2 (pt) | composto , composição farmacêutica , método para o tratamento do câncer , processo para a preparação de uma composição farmacêutica , conjunto , utilização de um composto e invenção. | |
BR112015003201A2 (pt) | composto, composição farmacêutica, uso de um composto e método para tratar ou melhorar o cãncer | |
BR112016018418A2 (pt) | Composto, uso do mesmo, e composição farmacêutica | |
BR112015009567A2 (pt) | compostos de benzil sulfonamida novos úteis como inibidores de mogat-2 | |
BR112016013946A8 (pt) | quinazolin-thf-aminas como inibidores de pde1, composição farmacêutica que os compreende, processo para preparação da referida composição farmacêutica, bem como uso dos composto e kit | |
EA201590656A1 (ru) | Азаиндолины | |
BR112015007312A2 (pt) | composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção | |
EA201692045A1 (ru) | Производное фенантролинфосфоновой кислоты и способ его получения и применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |